474: Assessing safety and efficacy of Neoral®/everolimus maintenance therapy in cardiac transplant recipients: 12 month data

Abstract

between 1996-2005. Methods and Materials: In a 10 year period between 1996-2005 seventy patients with CF underwent transplantation . Demographics: m/f 34/36. 66 (94%) pts received a double lung TX, 2 (3%) a heart-lung TX and 2 (3%) a single lung TX . Mean age at time of TX was 25,3 8,4 years (range 9-50ys). In 39 patients (55%) (group A) induction therapy with rabbitantithymocyte-globulin (ATG) was administered, group B consisted of 6 pats (8%) receiving Daclizumab and 25 (37%) patients with no induction therapy The mean time of follow up was 37,5 30,5 months. Results: Patients who received ATG (group A) for induction had 1, 3 and 5 year survival rates of 97%, 97% and 80%, patients who received Daclizumab or no induction agent (group B) had a 1, 3 and 5 year survival of 61%, 61% and 55% (log rank groupA vs group B p 0,0014). The use of induction therapy with ATG compared to no induction therapy or Daclizumab resulted in fewer episodes of acute rejection ISHLT grade A1 within the first 100days post-transplantion (p 0.013 ). One patient in group A died due to infectious complications on day 147 after TX, 12 patients in group B died during the first postoperative 6 months (reason for death: septicaemia n 8, POF n 2, others n 2). In both groups freedom from BOS was 98% , 92% and 84 % after 1, 3 and 5 years , respectively. Conclusions: Induction therapy with ATG in patients with CF demonstrates excellent long-term survival rates and a low incidence of acute rejections compared to induction therapy with Daclizumab or no induction. A significant lower rate of severe infectious complications in the ATG group accounts for this improvement of survival.